Core Viewpoint - The company, Yunnan Lincang Xin Yuan Germanium Co., Ltd., has approved the establishment of a holding subsidiary, Yunnan Germanium Biotechnology Co., Ltd., through a joint investment of 10 million RMB with Kunming Haliwa Enterprise Management Partnership, focusing on the development of daily chemical products and other applications related to organic germanium [5][20]. Group 1: Investment Overview - The board of directors approved the investment to establish a holding subsidiary with a total capital of 10 million RMB, where the company will contribute 7 million RMB and Kunming Haliwa will contribute 3 million RMB [5][20]. - The new subsidiary will primarily engage in the development of daily chemical products centered around organic germanium [5][20]. Group 2: Subsidiary Details - The proposed subsidiary, Yunnan Germanium Biotechnology Co., Ltd., will have a registered capital of 10 million RMB and will be located in the Kunming High-tech Industrial Development Zone [8][9]. - The business scope of the subsidiary includes research and application of cell technology, production and sales of daily chemical products, and health consulting services, among others [8][9]. Group 3: Investment Purpose and Impact - The investment aims to cultivate a business segment with sustainable growth potential, extending the company's main business downstream and enhancing its industrial chain layout [20]. - The funding for this investment will come entirely from the company's own funds, ensuring that normal operations and financial stability are maintained [20].

Group 1 - Yunnan Zhenye (SZ 002428) announced the establishment of a new subsidiary, Yunnan Zhenye Biotechnology Co., Ltd., with a total investment of 10 million yuan [1] - The new subsidiary will focus on the development of daily chemical products and other applications related to organic germanium [1] - As of the announcement, Yunnan Zhenye's market capitalization is 19 billion yuan [1]